Definitive Contract 75N91023C00007
Award Date
2/28/23
Potential Completion Date
2/27/24
Potential Value
$340K
Federal Agency
National Cancer Institute
Awardee
Genomic Expression Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Beverly, MA 01915, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
21
Legislative Mandate
Service Contract Act
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
This $2,049,554 firm fixed price definitive contract was awarded by the National Cancer Institute, a civilian agency within the Department of Health and Human Services, to Sentimetrix, Inc., a for-profit small business. The contract supports the SBIR Phase II effort for "POSTURE ANALYSIS THROUGH MACHINE LEARNING (PATHML)," which was previously funded under a $454,907 SBIR Phase I contract in 2021. The PATHML effort aims to develop machine learning techniques to analyze human posture...
This $454,907 firm fixed price contract was awarded by the National Institutes of Health National Cancer Institute to Sentimetrix, Inc. for research under the SBIR Phase I topic "POSTURE ANALYSIS THROUGH MACHINE LEARNING (PATHML)". The contract is associated with the Department of Health and Human Services' National Institutes of Health and Centers for Disease Control and Prevention SBIR solicitation seeking innovative solutions across cancer research, infectious diseases, public...
This is a Firm Fixed Price contract awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to Neuralrad LLC, a small business, for $454,559.00. The contract was awarded under the SBIR (Small Business Innovation Research) program to support the development of "Quantitative Imaging Software Tools for Cancer Diagnosis and Treatment Planning" as described in the original solicitation. This Phase I SBIR contract has a period of performance from...
This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency, to Incogen Inc., a woman-owned small business. The contract, valued at $3,599,936, is for the development of "GENE EXPRESSION SIGNAL PROCESSING TOOLS FOR EARLY DETECTION OF CANCER" under Topic 197. It is a definitive, firm-fixed-price contract with a period of performance ending on December 14, 2009. The contract is set aside for small businesses.
<p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>
This is a $455,000 firm fixed price contract awarded by the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH) at the Department of Health and Human Services (HHS). The contract was awarded to Mrimath LLC, a small disadvantaged, woman-owned limited liability company, for a Small Business Innovation Research (SBIR) Phase I project related to Artificial Intelligence-aided imaging for cancer prevention, diagnosis, and monitoring. The contract has a...
This $354,994.00 federal contract award was made by the National Cancer Institute (NCI) to Columbus Nanoworks, Inc., a small business biotechnology research company, for a Phase I Small Business Innovation Research (SBIR) project titled "POSTURE ANALYSIS THROUGH MACHINE LEARNING (PATHML)." The project is focused on developing a quantum-based diagnostic for microRNA in inflammatory breast cancer, which aligns with NCI's broader research objectives in cancer diagnostics and...
<p>This is a $198,751 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Genomic Systems, LLC. The contract is for research and development in the TAS::75 0849::TAS area and has a period of performance ending on September 30, 2011. This SBIR Phase I contract was awarded on a Firm Fixed Price basis.</p>
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Detroit R&D, Inc., a minority-owned, economically disadvantaged, woman-owned small business. The contract is for R&D in biomedical basic research with a ceiling value of $299,097. The contract is a definitive, firm-fixed-price contract with a period of performance ending on September 21, 2016. This SBIR Phase I award will support the development of...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Mediomics LLC, a woman-owned small business. The contract is for the development of glycosylation-specific research under SBIR Topic 294, with a ceiling value of $148,569. SBIR contracts are set-aside for small businesses to engage in research and development for the government. This Phase I contract represents the initial research and feasibility...